InflaRx NV (IFRX)
1.56
+0.04
(+2.63%)
USD |
NASDAQ |
Jun 14, 16:00
1.58
+0.02
(+1.28%)
Pre-Market: 20:00
InflaRx Research and Development Expense (Annual): 44.41M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 44.41M |
| December 31, 2022 | 39.57M |
| December 31, 2021 | 42.24M |
| December 31, 2020 | 29.33M |
| December 31, 2019 | 49.91M |
| Date | Value |
|---|---|
| December 31, 2018 | 29.55M |
| December 31, 2017 | 16.32M |
| December 31, 2016 | 5.842M |
| December 31, 2015 | 3.860M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
29.33M
Minimum
2020
49.91M
Maximum
2019
41.09M
Average
42.24M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Affimed NV | 102.80M |
| MorphoSys AG | 307.04M |
| BioNTech SE | 1.930B |
| Immatics NV | 128.47M |
| CureVac NV | 125.28M |